{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Robert", "organization": "", "rank": 1, "lastname": "CYRAN"}], "original": "By ROBERT CYRAN"}, "news_desk": "Business", "slideshow_credits": null, "abstract": null, "multimedia": [], "headline": {"content_kicker": "Breakingviews", "main": "Valeant\u2019s Struggles Are a Bad Omen for the Entire Industry"}, "print_page": null, "keywords": [{"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Valeant Pharmaceuticals International Inc", "is_major": "N", "rank": "2", "name": "organizations"}, {"value": "Company Reports", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Amgen Inc", "is_major": "N", "rank": "4", "name": "organizations"}, {"value": "AmerisourceBergen Corp", "is_major": "N", "rank": "5", "name": "organizations"}, {"value": "Endo International PLC", "is_major": "N", "rank": "6", "name": "organizations"}, {"value": "Express Scripts Inc", "is_major": "N", "rank": "7", "name": "organizations"}], "snippet": "Intensifying pressure stands to upend business models heavily dependent on raising prices....", "source": "The New York Times", "lead_paragraph": "Intensifying pressure stands to upend business models heavily dependent on raising prices.", "word_count": "381", "pub_date": "2016-11-08T18:38:54Z", "subsection_name": "DealBook", "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/11/09/business/dealbook/valeants-struggles-are-a-bad-omen-for-the-entire-industry.html", "_id": "58221bc67c459f6a5fccce68"}